# A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout

> **NCT04956432** · PHASE3 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 779 (actual)

## Conditions studied

- Gout

## Interventions

- **DRUG:** SHR4640
- **DRUG:** Allopurinol

## Key facts

- **NCT ID:** NCT04956432
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-15
- **Primary completion:** 2023-12-13
- **Final completion:** 2024-08-23
- **Target enrollment:** 779 (ACTUAL)
- **Last updated:** 2025-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04956432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04956432, "A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04956432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*